kbc technology news (text/Li Taihong) Taiwan Biotechnology Factory Xunlian Biotechnology has fully sprinted cell therapy. In addition to its existing chronic wound healing and degenerative arthritis cell treatment, it has also entered the two major fields of terminal cancer treatment and medical beauty, and entered cancer immune cell therapy and the combined treatment of minimally invasive medical beauty surgery with a large market scale.
, Chairman of Xunlian, Cai Zhengxian, said that cell therapy has become a global science, with medical policy support, and the medical needs of patients have the opportunity to be met. The company is ready to do its best, from terminal cancer treatment to minimally invasive combination of medical beauty skin or auxiliary therapy, it will become an important force in Taiwan's cell therapy industry chain to open up international medical care.
Xunlian said that the company's cell therapy application plan has covered 6 major areas: orthopedics, rheumatism and immunology, plastic surgery, dermatology, medical beauty, tumor immunotherapy, including degenerative arthritis, chronic wound healing, minimally invasive skin and cancer immune cell therapy. The cooperative implementation hospitals include Taiwan's Sanjun General Hospital, Xinguang Hospital, large medical centers in Taichung and northern China, and the Milan Fashion Clinic of the medical beauty chain group Milan Fashion Clinic.
Xunlian said that according to statistics, the global medical beauty scope includes medical beauty cosmetics, non-surgical plastic surgery and plastic surgery. It is expected that by 2023, the global plastic surgery market will reach US$21.97 billion. In the future, under the issue of anti-aging and the increase in demand in emerging markets, it will drive the development of the medical beauty industry.
In addition to its own technology, Xunlian has identified the future trend of cell therapy and has also established a standard cell culture laboratory that complies with GTP (Good Operating Specifications for Human Cell Tissue) 10 years ago. Recently, it has also extended another business: cell commissioned research and commissioned manufacturing. According to Energias Market Research, the global regenerative pharmaceutical market is expected to reach US$79.8 billion in 2024, with a compound growth rate of 20.5% from 2018 to 2024. (Proofreading/Jurnan)
Xunlian Chairman Cai Zhengxian (Picture source: Xin Technology)
